Immunotherapy plus chemo before surgery for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage IIIB or IIIC non-small cell lung cancer (a common type of lung cancer).
- You are generally in good health and can care for yourself, with little or no help.
- You have at least one tumor that can be measured on scans.
- Your major organs (like liver, kidneys, and blood cells) are working well enough to handle the treatment.
- Your lungs are strong enough to tolerate surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
Hear when a new Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.